1-3 of 3
Trevor Newhook, MS
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-Cell Lymphoma (PTCL) in Adults Age 60 and Above

Christopher A. Yasenchak, MD, Rodolfo Bordoni, MD, Victor Yazbeck, MD, Dipti Patel-Donnelly, MD, Timothy Larson, MD, Trevor Newhook, MS, Linda Ho, Matthew Mei, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2852.
https://doi.org/10.1182/blood-2019-122968
Published: 2019
Journal Articles

Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥60 Years

Christopher A. Yasenchak, MD, Rodolfo Bordoni, MD, Victor Yazbeck, MD, Dipti Patel-Donnelly, MD, Thomas Anderson, Timothy Larson, MD, Trevor Newhook, MS, Matthew Mei, MD, Linda Ho, Jonathan W. Friedberg, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 237.
https://doi.org/10.1182/blood-2019-124866
Published: 2019
Journal Articles

A Phase 2 Study of Retreatment with Brentuximab Vedotin in Patients with cHL, sALCL or Other CD30-Expressing PTCL

Sairah Ahmed, MD, Julie Lisano, PharmD, Trevor Newhook, MS
Journal: Blood
Blood (2019) 134 (Supplement_1): 4054.
https://doi.org/10.1182/blood-2019-121523
Published: 2019